Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese Adverse Drug Event Report database

Documenti analoghi

• Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System
  di: Guanghan Sun, et al.
  Pubblicazione: (2025)
• Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database
  di: Zhanzhang Wang, et al.
  Pubblicazione: (2024)
• Comprehensive analysis of adverse event profile changes with pertuzumab addition to trastuzumab‐based breast cancer therapy: Disproportionality analysis using VigiBase
  di: Tatsuaki Takeda, et al.
  Pubblicazione: (2025)
• Disproportionality Analysis of Intravitreal Ranibizumab, Aflibercept, and Brolucizumab for Cardiovascular and Cerebrovascular Events
  di: Keisuke Nosaka, et al.
  Pubblicazione: (2025)
• Pharmacovigilance of obeticholic acid: An analysis of the Food and Drug Administration Adverse Event Reporting System database
  di: Qining He, et al.
  Pubblicazione: (2025)